MORGAN STANLEY PLC/CALL/AMGEN/460/0.1/17.01.25 | Real-time Bid/Ask 05:22:04 2024-07-01 EDT | ||
| 0.25 EUR / 0.34 EUR | +9.26% |
|
| Current month | +12.50% | ||
| 1 month | +8.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.27 | 0.00% |
| 24-06-28 | 0.27 | 0.00% |
| 24-06-27 | 0.27 | -6.90% |
| 24-06-26 | 0.29 | -6.45% |
| 24-06-25 | 0.31 | +3.33% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 03:18 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME6QP8 |
| ISIN | DE000ME6QP82 |
| Date issued | 2024-01-10 |
| Strike | 460 $ |
| Maturity | 2025-01-17 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.36 € |
|---|---|
| Lowest since issue | 0.103 € |
| Spread | 0.08 € |
| Spread % | 24.24% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.4
USD
Average target price
316.4
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
